Novo Nordisk (NVON) Price & Analysis

NVON Stock Chart & Stats

MX$746.28MX$17.28(2.37%)

At close: Oct 30 4:00 PM EDT

Day’s Range: MXN 729.00 - MXN 754.00
52-Week Range: MXN 637.43 - MXN 1,119.03
Previous Close: MXN 729.00
Volume: 2,604
Average Volume (3M): 3,704
Market Cap: MXN 3.31T
Enterprise Value: MXN 227.20B
Total Cash (Recent Filing): MXN 44.98B
Total Debt (Recent Filing): MXN 140.13B
Price to Earnings (P/E): 10.1
Beta: 0.07
Next Earnings: Nov 04, 2026
EPS Estimate: 13.73
Next Dividend Ex-Date: N/A
Dividend Yield: 4.10%

Bulls Say, Bears Say

Bulls Say

Exceptional Growth And Profitability

Novo combines rapid revenue expansion with unusually high profitability, indicating strong product economics and pricing power in chronic-care medicines. These margins can support substantial reinvestment in manufacturing, commercial expansion and research while providing resilience through normal business-cycle fluctuations.

Leading GLP-1 Market Position

The strong position across injectable and oral obesity treatments demonstrates substantial commercial execution, brand strength and patient adoption. Oral-market leadership also broadens the addressable market and may help Novo retain relevance as treatment preferences evolve and obesity care expands internationally.

Pipeline And Licensing Expansion

The HRS-1596 license adds a potential once-weekly oral therapy to Novo’s obesity pipeline and strengthens access to next-generation mechanisms. Although development remains uncertain, the deal broadens future product options and supports ongoing innovation beyond the current semaglutide franchise.

Bears Say

Challenging 2026 Outlook

Management’s flat-to-declining 2026 outlook signals that near-term growth is being pressured by lower realized prices, competition, coverage reductions and semaglutide exclusivity losses. These forces could persist across the next several quarters and make recent exceptional growth harder to sustain.

Higher Leverage And Weaker Cash Conversion

The sharp increase in borrowing reduces financial flexibility relative to the company’s earlier balance-sheet position, while weak free-cash-flow conversion limits the cash cushion behind reported earnings. Continued investment and capital returns will therefore require closer discipline if product conditions soften.

Clinical Pipeline Setback

ZEUS weakens the potential contribution of ziltivekimab and highlights the uncertainty of Novo’s expansion into higher-risk disease areas. The result may also increase reliance on obesity and diabetes programs, making successful development and commercialization of replacement pipeline assets more important.

Novo Nordisk News

The Week That Was, The Week Ahead: Macro and Markets, November 1

U.S. stocks ended Friday sharply lower as disappointing technology earnings and concerns over massive AI spending sent Wall Street into another sell-off. The Dow Jones Industrial Average (DJIA) fell 1.09%

6h agoC O

Cboe data suggests bullish flow in Novo Nordisk with shares up 1.49%

Cboe data suggests bullish flow in Novo Nordisk (NVO), with shares up 58c, or 1.49%, near $39.73. Options volume more than double the daily average with 49k contracts traded and

2d agoNVO NOV

AbbVie Science Chief says interested in building out obesity assets

AbbVie (ABBV) Chief Scientific Officer Roopal Thakkar said on the company’s earnings call: “Yes, we continue to have interest to build out obesity assets. We are open to anything that

2d agoLLY NVO

Moderately bullish activity in Novo Nordisk with shares up 1.27%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 48c, or 1.27%, near $38.77. Options volume roughly in line with average with 18k contracts traded and calls leading puts

3d agoNVO NOV

Novo Stock (NVO) Falls After Another Head-to-Head Obesity Trial Loss to Eli Lilly

Shares of Danish pharma giant Novo ($NVO) edged lower to around $38 on Wednesday afternoon. This came after rival drugmaker Eli Lilly ($LLY) announced results of a head-to-head trial in

3d agoMS LLY

Novo Nordisk Advances Mim8 Trial in Rare Haemophilia A, Expanding Its Specialty Pipeline

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study “A Multinational, Open-label Study to Investigate Efficacy and Safety of Denecimig (Mim8) in Adults With Acquired Haemophilia

3d agoNVO

Moderately bullish activity in Novo Nordisk with shares up 0.24%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 10c, or 0.24%, near $39.15. Options volume relatively light with 26k contracts traded and calls leading puts for a put/call

5d agoNVO NOV

Wall Street Has High Expectations for Eli Lilly Stock (LLY) Heading into Earnings

The company report earnings on Oct. 29.

5d agoGS BAC

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Novo Nordisk ( ($NVO) ) just unveiled an announcement. On 26 October 2026, Novo Nordisk reported progress in a major share repurchase programme that forms part of a broader DKK

5d ago6K NVO

FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older

The U.S. Food and Drug Administration has approved Awiqli injection, a long-acting insulin analog, as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10

1w agoNVO NOV

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)

WSW, NY, October 21st, 2026, FinanceWire Recent acquisitions and licensing deals reveal what drugmakers want next: different biology, better dosing and treatments that can complement existing medicines. Palatin is developing

1w agoNVO PTN

Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data

Novo Nordisk stock gained on Tuesday alongside new weight-loss data from women who used CagriSema.

1w agoLLY NVO

Eli Lilly Stock (LLY) Hits All-Time High Ahead of Earnings

The pharma giant reports financial results on Oct. 29.

1w agoGS BAC

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.76%

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 30c near $38.53. Options volume roughly in line with average with 65k contracts traded and puts leading

1w agoNVO NOV

NVON FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was Mex$637.43 and its highest was Mex$1119.03 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is Mex$3.31T.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Aug 04, 2026. The company reported Mex$17.941 earnings per share for the quarter, beating the consensus estimate of Mex$14.465 by Mex$3.475.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.

Does Novo Nordisk pay dividends?

Novo Nordisk does not currently pay dividends.

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 13.73.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of Mex$17.941 in its last earnings report, beating expectations of Mex$14.465. Following the earnings report the stock price went down -6.432%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in MX:NVON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Novo Nordisk Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Novo Nordisk

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NVON) Earnings & Revenues

Historic Earnings Reports

NVON Company Deck

NVON Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call was broadly constructive, supported by strong GLP-1 volume growth, rapid Wegovy pill uptake in the U.S. and international markets, continued pipeline advancement, Q2 sales growth of 7%, operating profit growth of 11%, and transformation savings ahead of plan. However, the company faces material headwinds from lower realized prices, declining gross margin, U.S. competition and coverage pressure, semaglutide loss of exclusivity, declining international market share, and the unsuccessful ZEUS cardiovascular outcomes trial. Overall, the highlights significantly outweigh the lowlights, although management characterized 2026 as a challenging year.

View all MX:NVON earnings summaries

NVON Stock 12 Month Forecast

Average Price Target

MXN 793.78▲(6.37% Upside)

Past 12 Months12 Month ForecastJan2026Oct2026

HighMXN 877.14

AverageMXN 793.78

LowMXN 746.51

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	11	4	7
Technical Analysis	3	4	3
Moving Averages	8	0	4

Technical Analysis >

Similar Stocks

Stocks similar to MX:NVON
Company	Price & Change	Follow
AMGNAmgen
LLYEli Lilly & Co
MRKMerck & Company
NVSNovartis
SNYSanofi

Compare MX:NVON Stocks >

Ownership Overview

1.81% Mutual Funds
0.74% Other Institutional Investors
97.24% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft